Compare INUV & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | RGNT |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | N/A | 8 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 24.6M |
| IPO Year | 1996 | N/A |
| Metric | INUV | RGNT |
|---|---|---|
| Price | $1.26 | $3.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 142.2K | ★ 13.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $86,209,305.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.89 | N/A |
| P/E Ratio | $9.54 | ★ N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $1.21 | $1.23 |
| 52 Week High | $6.27 | $15.50 |
| Indicator | INUV | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 31.45 | 53.12 |
| Support Level | N/A | $1.95 |
| Resistance Level | $2.01 | $7.80 |
| Average True Range (ATR) | 0.10 | 2.17 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 16.13 | 18.79 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.